Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | ELAVL1 | Q15717 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MYC | P01106 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.36 |
| ▸ | MPL | P40238 | 1/20 | 0.35 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20485 | 0.86 | ALDH1A1 (0.35) | ALDH1A1GAAMEP1BMEN1KMT2A | |
| SCHEMBL242277 | 0.86 | TAAR1 (0.38) | ALDH1A1GAAMEP1BMEN1KMT2A | |
| SCHEMBL30716894 | 0.85 | AMY1A (0.44) | ALDH1A1GAAMEP1BMEN1KMT2A | |
| SCHEMBL1607815 | 0.85 | RAPGEF4 (0.44) | ALDH1A1GAAMEP1BMEN1KMT2A | |
| SCHEMBL30236538 | 0.85 | RAPGEF4 (0.44) | ALDH1A1GAAMEP1BMEN1KMT2A | |
| SCHEMBL30823619 | 0.85 | GAA (0.41) | ALDH1A1GAAMEP1BMEN1KMT2A | |
| SCHEMBL14991279 | 0.85 | AMY1A (0.44) | ALDH1A1GAAMEP1BMEN1KMT2A | |
| SCHEMBL1180196 | 0.85 | GAA (0.41) | ALDH1A1GAAMEP1BMEN1KMT2A | |
| SCHEMBL1806434 | 0.83 | ALDH1A1 (0.37) | ALDH1A1GAAMEP1BMEN1KMT2A | |
| SCHEMBL1806437 | 0.83 | MPL (0.38) | ALDH1A1GAAMEP1BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110504017-B | Preparation and application method of tracer | 哈尔滨医科大学 | 2022-06-10 | — | — | CN | claimed |
| CN-112752740-A | Process for the preparation of fluoromethyl-18 labelled radiopharmaceutical agents using selective azide substitution and precursor scavenging | BIK治疗公司 | 2021-05-04 | — | — | CN | claimed |
| WO-2020059986-A1 | METHOD FOR PREPARING FLUORINE-18-LABELED FLUOROMETHYL-SUBSTITUTED RADIOPHARMACEUTICALS USING SELECTIVE AZIDE SUBSTITUTION REACTION AND PRECURSOR SCAVENGING | 주식회사 바이오이미징코리아 | 2020-03-26 | — | — | WO | claimed |
| US-12274760-B2 | Method for preparing fluorine-18-labeled fluoromethyl-substituted radiopharmaceuticals using selective azide substitution reaction and precursor scavenging | BIK THERAPEUTICS INC. (KR) | 2025-04-15 | — | — | US | disclosed |
| US-20210205482-A1 | METHOD FOR PREPARING FLUORINE-18-LABELED FLUOROMETHYL-SUBSTITUTED RADIOPHARMACEUTICALS USING SELECTIVE AZIDE SUBSTITUTION REACTION AND PRECURSOR SCAVENGING | LEE, BYUNG CHUL (KR) | 2021-07-08 | — | — | US | disclosed |
| EP-3842405-A1 | METHOD FOR PREPARING FLUORINE-18-LABELED FLUOROMETHYL-SUBSTITUTED RADIOPHARMACEUTICALS USING SELECTIVE AZIDE SUBSTITUTION REACTION AND PRECURSOR SCAVENGING | BIK Therapeutics Inc. (KR) | 2021-06-30 | — | — | EP | disclosed |
| CN-112752740-A | Process for the preparation of fluoromethyl-18 labelled radiopharmaceutical agents using selective azide substitution and precursor scavenging | BIK治疗公司 | 2021-05-04 | — | — | CN | disclosed |
| CN-112752740-A | Process for the preparation of fluoromethyl-18 labelled radiopharmaceutical agents using selective azide substitution and precursor scavenging | BIK治疗公司 | 2021-05-04 | — | — | CN | disclosed |
| US-10710968-B2 | Radiolabeled erlotinib analogs and uses thereof | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2020-07-14 | — | — | US | disclosed |
| WO-2020059986-A1 | METHOD FOR PREPARING FLUORINE-18-LABELED FLUOROMETHYL-SUBSTITUTED RADIOPHARMACEUTICALS USING SELECTIVE AZIDE SUBSTITUTION REACTION AND PRECURSOR SCAVENGING | 주식회사 바이오이미징코리아 | 2020-03-26 | — | — | WO | disclosed |
| US-20190023664-A1 | RADIOLABELED ERLOTINIB ANALOGS AND USES THEREOF | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2019-01-24 | — | — | US | disclosed |
| WO-2013001088-A1 | DIRECT SYNTHESIS OF 18F-FLUOROMETHOXY COMPOUNDS FOR PET IMAGING AND THE PROVISION OF NEW PRECURSORS FOR DIRECT RADIOSYNTHESIS OF PROTECTED DERIVATIVES OF O-([18F]FLUOROMETHYL) TYROSINE | PIRAMAL IMAGING SA (CH) | 2013-01-03 | — | — | WO | disclosed |
| EP-2540710-A1 | New precursors for direct radiosynthesis of protected derivatives of O-([18F]Fluoromethyl) tyrosine | Bayer Schering Pharma Aktiengesellschaft (DE) | 2013-01-02 | — | — | EP | disclosed |
| US-20120177988-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-07-12 | — | — | US | disclosed |
| WO-2012052556-A1 | NOVEL HALOALKOXYQUINAZOLINES, AND PREPARATION AND USE THEREOF | UNIVERSITÄT LEIPZIG (DE) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012040138-A2 | NOVEL RADIOTRACER | GE HEALTHCARE LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012040151-A2 | ISOTOPIC CARBON CHOLINE ANALOGS | GE HEALTHCARE LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012040133-A2 | NOVEL PRECURSOR | GE HEALTHCARE LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
| US-20120070731-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20090325065-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10710968-B2 | Radiolabeled erlotinib analogs and uses thereof | EGFR, KRAS, ERBB4 | ALDH1A1 2112/4885GAA 1038/4885MEP1B 927/4885 |
| US-20210205482-A1 | METHOD FOR PREPARING FLUORINE-18-LABELED FLUOROMETHYL-SUBSTITUTED RADIOPHARMACEUTICALS USING SELECTIVE AZIDE SUBSTITUTION REACTION AND PRECURSOR SCAVENGING | KCNK18, CYP4F8, CYP2F1 | ALDH1A1 4358/4885GAA 3666/4885MEP1B 2179/4885 |
| US-12274760-B2 | Method for preparing fluorine-18-labeled fluoromethyl-substituted radiopharmaceuticals using selective azide substitution reaction and precursor scavenging | KCNK18, CYP4F8, CYP2F1 | ALDH1A1 4358/4885GAA 3666/4885MEP1B 2179/4885 |
| US-20190023664-A1 | RADIOLABELED ERLOTINIB ANALOGS AND USES THEREOF | EGFR, KRAS, ERBB4 | ALDH1A1 2112/4885GAA 1038/4885MEP1B 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.